Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is hunting for new patients to maintain its crown as Europe’s most valuable company.
The pharmaceutical giant beat analyst expectations after growing both sales and operating profits by 25% in 2024. As was the case in both 2022 and 2023, its commercialized GLP-1 medication for weight loss was the overwhelming driver of sales.
